1: Pramana KAAP, Cahyani NGAMSD, Pintaningrum Y, Rahmat B. New insight of the efficacy trimetazidine in patients with peripheral arterial disease: a meta- analysis. Egypt Heart J. 2024 Mar 6;76(1):31. doi: 10.1186/s43044-024-00461-x. 2: Pușcaș A, Ștefănescu R, Vari CE, Ősz BE, Filip C, Bitzan JK, Buț MG, Tero- Vescan A. Biochemical Aspects That Lead to Abusive Use of Trimetazidine in Performance Athletes: A Mini-Review. Int J Mol Sci. 2024 Jan 28;25(3):1605. doi: 10.3390/ijms25031605. 3: Khanra S, Reddy P, Giménez-Palomo A, Park CHJ, Panizzutti B, McCallum M, Arumugham SS, Umesh S, Debnath M, Das B, Venkatasubramanian G, Ashton M, Turner A, Dean OM, Walder K, Vieta E, Yatham LN, Pacchiarotti I, Reddy YCJ, Goyal N, Kesavan M, Colomer L, Berk M, Kim JH. Metabolic regulation to treat bipolar depression: mechanisms and targeting by trimetazidine. Mol Psychiatry. 2023 Aug;28(8):3231-3242. doi: 10.1038/s41380-023-02134-8. Epub 2023 Jun 29.
合成参考文献
摘要:United States Patent Document., #3262852 参考文献:10.1007/bf03190575 摘要:Génissel P, Chodjania Y, Demolis JL, Ragueneau I, Jaillon P. Assessment of the sustained release properties of a new oral formulation of trimetazidine in pigs and dogs and confirmation in healthy human volunteers. European Journal of Drug Metabolism and Pharmacokinetics. 2004 Mar;29(1):61–8. doi: 10.1007/bf03190575. 参考文献:10.2165/00129784-200101010-00003 摘要:Schofield RS, Hill JA. Role of Metabolically Active Drugs in the Management of Ischemic Heart Disease. American Journal of Cardiovascular Drugs. 2001 Jan;1(1):23–35. doi: 10.2165/00129784-200101010-00003.